Teladoc Health (NYSE:TDOC) Updates Q3 2026 Earnings Guidance

Teladoc Health (NYSE:TDOC) updated its third quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of -0.300–0.200 for the period, compared to the consensus earnings per share estimate of -0.170. The company issued revenue guidance of $569.0 million-$609.0 million, compared to the consensus revenue estimate of $629.1 million. Teladoc Health also updated its FY 2026 guidance to -1.000–0.750 EPS.

Teladoc Health Trading Up 1.1%

Shares of NYSE:TDOC traded up $0.07 during midday trading on Friday, reaching $6.66. The company had a trading volume of 2,899,481 shares, compared to its average volume of 5,524,203. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.72 and a current ratio of 2.80. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $9.89. The company has a fifty day simple moving average of $8.21 and a two-hundred day simple moving average of $6.54. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -6.72 and a beta of 2.10.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. Teladoc Health had a negative return on equity of 12.02% and a negative net margin of 7.13%.The firm had revenue of $606.93 million for the quarter, compared to the consensus estimate of $615.44 million. During the same quarter in the prior year, the company posted ($0.19) earnings per share. The firm’s revenue was down 4.0% on a year-over-year basis. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Research analysts predict that Teladoc Health will post -0.92 earnings per share for the current year.

Analyst Ratings Changes

TDOC has been the topic of several recent research reports. Citigroup raised their price target on Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a report on Tuesday, May 5th. Bank of America boosted their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a report on Tuesday, July 7th. Weiss Ratings raised shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Finally, Canaccord Genuity Group lowered their price objective on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday. Five equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.50.

Insider Activity

In other Teladoc Health news, insider Fernando M. Rodrigues sold 5,677 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $43,315.51. Following the completion of the sale, the insider directly owned 9,572 shares in the company, valued at $73,034.36. This represents a 37.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Carlos Nueno sold 6,196 shares of Teladoc Health stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $47,275.48. Following the completion of the transaction, the insider owned 57,671 shares in the company, valued at approximately $440,029.73. The trade was a 9.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 39,195 shares of company stock valued at $299,058. 0.70% of the stock is owned by insiders.

Key Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a second-quarter adjusted loss of $0.21 per share, better than the $0.24 loss analysts expected. Integrated Care and international operations helped offset weakness in BetterHelp, while first-half losses narrowed, suggesting efficiency initiatives are making progress. Teladoc Health Q2 Earnings Beat Estimates on Integrated Care Strength
• Positive Sentiment: Canaccord Genuity maintained a “buy” rating despite lowering its price target from $11 to $10, implying substantial upside from recent trading levels. Increased call-option activity also indicates that some traders are positioning for a rebound. Canaccord Lowers Teladoc Price Target
• Neutral Sentiment: Teladoc generated $64.7 million in operating cash flow and ended the quarter with $774.3 million in cash and equivalents, providing liquidity while the company works to stabilize revenue and reach sustained profitability. Teladoc Health Reports Second Quarter 2026 Results
• Negative Sentiment: Second-quarter revenue fell 4% year over year to $606.9 million, missing the roughly $615.4 million consensus estimate. The company posted a $38.9 million net loss, or $0.21 per share, compared with a $0.19 loss a year earlier. Teladoc Tumbles on Revenue Forecast Cut
• Negative Sentiment: Management reduced full-year 2026 revenue guidance to approximately $2.4 billion, below the $2.5 billion analyst consensus. Third-quarter revenue guidance of $569 million to $609 million and an adjusted loss of $0.30 to $0.20 per share were also below expectations. Why Teladoc Health Stock Is Dropping Following Soft Q3 Outlook
• Negative Sentiment: The primary concern is a shift in BetterHelp demand, including lower cash-pay revenue, which overshadowed strength in Integrated Care and raised doubts about Teladoc’s near-term growth and profit trajectory.

Institutional Trading of Teladoc Health

A number of hedge funds have recently added to or reduced their stakes in TDOC. IFP Advisors Inc increased its holdings in shares of Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock worth $31,000 after buying an additional 3,210 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Teladoc Health by 177.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 2,810 shares in the last quarter. Van ECK Associates Corp grew its position in Teladoc Health by 101.4% during the 4th quarter. Van ECK Associates Corp now owns 9,150 shares of the health services provider’s stock worth $64,000 after acquiring an additional 4,607 shares during the last quarter. Johnson Financial Group Inc. grew its position in Teladoc Health by 41,045.8% during the 3rd quarter. Johnson Financial Group Inc. now owns 9,875 shares of the health services provider’s stock worth $76,000 after acquiring an additional 9,851 shares during the last quarter. Finally, Cibc World Markets Corp acquired a new position in Teladoc Health in the 4th quarter worth about $82,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.